Fig. 1

Fcmr inhibits myeloid cell-dependent anti-tumor immunity. a Tumor growth (left) and mouse survival (right) curves of Fcmr^−/− and Fcmr^+/+ littermate mice that received ventral–lateral intradermal B16F0 cell transplants (2 × 10⁵ cells) at a site superior to the inguinal LN. Data are from one trial (n = 9 Fcmr^+/+ and 8 Fcmr^−/− mice), and representative of 2 separate experiments. b–d CTL:Treg ratios in B16F0 tumors in the Fcmr^−/− and Fcmr^+/+ mice in (a). b Left: Representative Treg flow cytometry data obtained from the analysis of B16F0 tumors harvested from Fcmr^−/− and Fcmr^+/+ mice. Right: Quantification of the data in the left panel normalized to tumor mass. c CTL:Treg ratio calculated as the number of CD8α⁺ T cells per FoxP3⁺ CD4⁺ T cells. See Supplementary Fig. 1 for data summary and gating strategy. d Correlation of the CTL:Treg ratio in (c) with the tumor mass at time of analysis. Data are pooled from 2 separate experiments (total n = 11 Fcmr^+/+ and 12 Fcmr^−/− mice). e Representative flow cytometry plots for intratumor myeloid cell populations, showing the gating strategy. f Quantification of the indicated cell subsets normalized to tumor mass (n = 5 Fcmr^+/+ and 5 Fcmr^−/− mice). g Tumor growth (left) and mouse survival (right) curves of Fcmr^fl/fl;LysMCre⁺ and Fcmr^fl/fl littermate mice that received B16F0 cells as described in (a). (n = 17 Fcmr^fl/fl and 7 Fcmr^fl/fl; LysMCre⁺ mice). Data are represented as mean ± SEM (ANOVA, t test, linear regression; *p < 0.05; **p < 0.01; ***p < 0.001)